Structure Therapeutics (GPCR) Return on Capital Employed (2023 - 2026)
Structure Therapeutics' (GPCR) quarterly Return on Capital Employed came in at 14.08% in Q1 2026, up 743.0% year-on-year from 1.67% in Q1 2025, and up 8.72% quarter-over-quarter from 15.42% in Q4 2025.
Structure Therapeutics (GPCR) Return on Capital Employed (2023 - 2026) Analysis & Trends
Structure Therapeutics' Return on Capital Employed history runs 4 years deep, the most recent figure standing at 14.08% for Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 743.0% year-over-year to 14.08% in Q1 2026; TTM through Mar 2026 was 14.08%, a 743.0% increase from a year earlier, with the FY2025 full-year figure at 14.96%, up 914.0% from the prior year.
- Return on Capital Employed improved to 14.08% in Q1 2026 per GPCR's latest filing, from 15.42% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 14.08% in Q1 2026 and bottomed at 41.78% in Q3 2023.
- The 4-year median for Return on Capital Employed is 25.81% (2024), against an average of 25.4%.
- Across the five-year window, Return on Capital Employed surged 2610 bps in 2024 and sank 1661 bps in 2025, its largest moves.
- Year by year, Return on Capital Employed stood at 31.68% in 2023, then jumped by 43 bps to 17.93% in 2024, then climbed by 14 bps to 15.42% in 2025, then advanced by 9 bps to 14.08% in 2026.
- Per Business Quant, the three latest GPCR Return on Capital Employed figures stand at 14.08% (Q1 2026), 15.42% (Q4 2025), and 32.29% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Structure Therapeutics | 11.04 Bn | 11.04 Bn | - | -14.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.08% |
| Dec 31, 2025 | -15.42% |
| Sep 30, 2025 | -32.29% |
| Jun 30, 2025 | -27.37% |
| Mar 31, 2025 | -21.51% |
| Dec 31, 2024 | -17.93% |
| Sep 30, 2024 | -15.68% |
| Jun 30, 2024 | -18.02% |
| Mar 31, 2024 | -25.81% |
| Dec 31, 2023 | -31.68% |
| Sep 30, 2023 | -41.78% |
| Jun 30, 2023 | -31.91% |
| Mar 31, 2023 | -36.67% |